Molecular Mechanisms of Atrial Fibrillation: A Multimodal Analysis Read more about Molecular Mechanisms of Atrial Fibrillation: A Multimodal Analysis
Pre-Employment Transition Services and Coordination Read more about Pre-Employment Transition Services and Coordination
OTIS/MotherToBaby Mailing Administrator Project Read more about OTIS/MotherToBaby Mailing Administrator Project
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema: The CONVERT II Trial Read more about An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema: The CONVERT II Trial
Pivotal Clinical Study of VDI's Ultra-High FrequencY Electrocardiogram (UHF-ECG) for the DiagNosis of VentriCular Electrical Dyssynchrony (VED): THE SYNC Study Read more about Pivotal Clinical Study of VDI's Ultra-High FrequencY Electrocardiogram (UHF-ECG) for the DiagNosis of VentriCular Electrical Dyssynchrony (VED): THE SYNC Study
Protocol Title : A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants with Advanced Solid Malignancies Read more about Protocol Title : A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants with Advanced Solid Malignancies
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase III Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Exp Read more about AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase III Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Exp
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the Read more about A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the
EVALUATION OF THE SAFETY AND THROMBOLYTIC EFFECTS OF ASCENDING DOSES OF TS23 (DS-9231) IN SUBJECTS WITH INTERMEDIATE-RISK (SUB-MASSIVE) ACUTE PULMONARY EMBOLISM Read more about EVALUATION OF THE SAFETY AND THROMBOLYTIC EFFECTS OF ASCENDING DOSES OF TS23 (DS-9231) IN SUBJECTS WITH INTERMEDIATE-RISK (SUB-MASSIVE) ACUTE PULMONARY EMBOLISM
